https://novapharmanews.com/eu/news/european-commission-approves-jascayd-nerandomilast-ipf-ppf 2026-07-19T21:17:55.342Z NovaPharmaNews en 2026-07-19T21:17:52.594Z JASCAYD (nerandomilast) Wins EU Approval for IPF & PPF nerandomilast, JASCAYD, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis https://novapharmanews.com/uploads/articles/european-commission-approves-jascayd-nerandomilast-ipf-ppf.webp JASCAYD (nerandomilast) Wins EU Approval for IPF & PPF https://novapharmanews.com/eu/news/vanda-pharmaceuticals-announces-ema-positive-opinion-for-orphan-drug-designation 2026-07-19T20:34:16.545Z NovaPharmaNews en 2026-07-19T20:27:30.424Z Vanda: EMA Positive Opinion for Imsidolimab in GPP imsidolimab, Rare Diseases, Dermatology, Immunology https://novapharmanews.com/apac/news/leqembi-real-world-leader-study-presented-at-aaic-2026-finds-over-75-of-early-al 2026-07-19T20:27:15.786Z NovaPharmaNews en 2026-07-19T20:27:15.786Z LEQEMBI LEADER Study: Real-World Data at AAIC 2026 https://novapharmanews.com/us/news/merck-lipfendra-enlicitide-oral-pcsk9-fda-approval 2026-07-19T20:08:35.571Z NovaPharmaNews en 2026-07-19T20:08:31.549Z Enlicitide Wins FDA Nod as First Oral PCSK9 Inhibitor